Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium.

By N. Mesaros, P. Nordmann, P. Plésiat, M. Roussel-Delvallez, J. Eldere, Y. Glupczynski, Y. Laethem, F. Jacobs, P. Lebecque, A. Malfroot and 2 more. Clinical Microbiology and Infection, 2007

633 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Molecular Biology, Molecular Medicine

View Paper: https://www.semanticscholar.org/paper/5468c554f3d94eb002c28134e84ed3c5cddcbe32

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Medicine

1. D. Yordanov
2. A. Croxatto
3. T. Strateva

Citations in the corpus

• How to manage Pseudomonas aeruginosa infections (2018, background): “These automated systems exhibit different performances between antibiotics with unreliable AST measurement for some components such as piperacillin-tazobactam, cefepime, and carbapenems that may require confirmation with other AST approaches including MIC determination [48].”
• Pseudomonas aeruginosa - a phenomenon of bacterial resistance. (2009, background): “aeruginosa is intrinsically resistant to many structurally unrelated antimicrobial agents (Mesaros et al., 2007) because of the low permeability of its outer membrane (1/100 of the permeability of E.”